ALLO - Allogene Therapeutics, Inc.
2.26
-0.150 -6.637%
Share volume: 6,330,340
Last Updated: 03-27-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$2.41
-0.15
-0.06%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-13-2024 | 08-07-2024 | 11-07-2024 | 03-13-2025 | 05-13-2025 | 08-13-2025 | 11-06-2025 | 03-12-2026 | |
| Assets | |||||||||
| Total Assets | 586.350 M | 646.883 M | 589.120 M | 548.710 M | 507.982 M | 470.593 M | 439.771 M | 415.905 M | |
| Current Assets | 395.364 M | 457.124 M | 304.415 M | 303.386 M | 291.576 M | 282.655 M | 260.719 M | 257.749 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 333.821 M | 273.961 M | 240.325 M | 217.258 M | 237.588 M | 220.788 M | 214.379 M | 198.522 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 51.039 M | 170.667 M | 51.239 M | 75.218 M | 42.455 M | 52.332 M | 37.815 M | 51.688 M | |
| Total Non-current Assets | 15.121 M | 1.134 M | 111.821 M | 80.673 M | 55.506 M | 29.510 M | 24.944 M | 8.043 M | |
| Property Plant Equipment | 95.931 M | 92.080 M | 88.989 M | 86.056 M | 82.992 M | 78.858 M | 75.896 M | 72.839 M | |
| Other Assets | 95.055 M | 97.679 M | 195.716 M | 159.268 M | 133.414 M | 109.080 M | 103.156 M | 85.317 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 586.350 M | 646.883 M | 589.120 M | 548.710 M | 507.982 M | 470.593 M | 439.771 M | 415.905 M | |
| Total liabilities | 124.983 M | 131.845 M | 125.372 M | 126.531 M | 122.589 M | 126.032 M | 124.442 M | 123.363 M | |
| Total current liabilities | 30.894 M | 37.305 M | 32.571 M | 35.523 M | 30.022 M | 31.675 M | 31.833 M | 32.514 M | |
| Accounts Payable | 5.779 M | 12.936 M | 5.506 M | 5.394 M | 5.058 M | 4.851 M | 3.699 M | 4.270 M | |
| Other liabilities | 94.089 M | 94.540 M | 92.801 M | 91.008 M | 92.567 M | 94.357 M | 92.609 M | 90.849 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 94.089 M | 94.540 M | 92.801 M | 91.008 M | 92.567 M | 94.357 M | 92.609 M | 90.849 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 461.367 M | 515.038 M | 463.748 M | 422.179 M | 385.393 M | 344.561 M | 315.329 M | 292.542 M | |
| Common stock | 2.090 B | 2.209 B | 2.223 B | 2.242 B | 2.265 B | 2.275 B | 2.287 B | 2.303 B | |
| Retained earnings | -1.627 B | -1.694 B | -1.760 B | -1.820 B | -1.880 B | -1.930 B | -1.972 B | -2.011 B |